New research suggests that patients who stop using new weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a leading health publication shows that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using these medications need to be cognizant of the potential of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery means a return to starting mass within about a year and a half.
Analyzing Treatments
The study, which examined dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with other pills.
Researchers note that individuals who shed pounds through diet and exercise generally have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Experts propose the mechanism of the injections accounts for the heightened weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
The NHS recommend the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of relapse, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who say that the findings "underscore the chronic nature of excess weight," similar to managing conditions like hypertension.
User Experiences
People who have stopped the jabs report a powerful return of cravings.
"I experienced something flipping and I was suddenly starving," described an individual.
This challenge is worsened if users have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, researchers stress that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on combined behavioural management.
